Pooled annual prevalence of GLP-1 RA use was 0.1 percent from 2018 to 2021 and increased to 0.4 percent by 2022.

Research reveals GLP-1 receptor agonists influence gut microbiome, enhancing metabolic health and offering anti-inflammatory ...

Medicare Advantage carriers have new reasons to believe the Trump administration will treat them more generously than the ...

Medicare Advantage insurers had urged CMS to scrap the obesity drug coverage proposals and eliminate a health equity payment ...

The candidate, which is still in early stages, targets the GLP-1, GIP and glucagon receptors. Novo’s blockbuster obesity and diabetes medications, Wegovy and Ozempic are GLP-1 receptor agonists, ...

a glucagon-like peptide-1 receptor/glucagon receptor dual agonist; and IBI-112, a novel long-acting anti-IL-23. In addition, it develops IBI-110, a novel anti-LAG3 monoclonal antibody; IBI-939 ...

Ask a Doctor is new series of physician-authored columns offering insights and advice on common health topics. It is not a substitute for seeking medical care.

Certain medications and supplements can disrupt this balance and cause sulfur burps. They include: Wegovy and other glucagon-like peptide-1 (GLP-1) receptor agonists that are now prescribed for weight ...

UBT251 is a long-acting synthetic peptide triple agonist targeting the receptors for GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide) and glucagon. It has ...

GLP-1 stands for glucagon-like peptide 1, and it regulates blood sugar, slows digestion, and regulates appetite, among other effects. GLP-1 drugs, like Ozempic or Wegovy, are receptor agonists ...

UBT251 is a long-acting synthetic peptide triple agonist targeting the receptors for GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide) and glucagon. It has ...